שווי כולל של החברה: Valneva SE (VALN)

Valneva SE (VALN) develops unique drugs against rare infections, targeting government agencies and tourists, while its Enterprise Value on the price chart stands at 614.40. Its status as a reputable European innovator allows the company to maintain leadership in preventive therapy. Operational resilience is ensured by outsourcing product filling to external CMO partners through long-term contracts, which eliminates production disruptions.

The indicator's formula reacts promptly to changes in liquidity and leverage. The metric determines the total cost of acquiring the business by summing market capitalization and net debt. This is critical for Valneva SE (VALN), as a high dependence on external CROs and distributors requires significant cash reserves. The enterprise value, accounting for net debt, allows for the tracking of financial stability during outsourcing. This chart's dynamics eliminate information gaps between reports.